Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin
- Conditions
- ThrombocytopeniaThrombosis
- Registration Number
- NCT00039858
- Lead Sponsor
- Encysive Pharmaceuticals
- Brief Summary
The purpose of this study is to evaluate the safe and effective dose of Argatroban for prophylaxis and/or treatment of thrombosis in pediatric patients with current or previous diagnosis of heparin-induced thrombocytopenia (HIT) and thrombosis syndrome (HITTS), or who in the opinion of the investigator require alternative anticoagulation due to an underlying condition.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 24
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (13)
Children's Hospital of Orange County
🇺🇸Orange, California, United States
Mattel Children's Hospital at UCLA
🇺🇸Los Angeles, California, United States
Children's Hospital of Boston
🇺🇸Boston, Massachusetts, United States
Michigan Congenital Heart Center
🇺🇸Ann Arbor, Michigan, United States
Primary Children's Medical Center
🇺🇸Salt Lake City, Utah, United States
Rush University Medical Center
🇺🇸Chicago, Illinois, United States
University of Chicago Children's Hospital
🇺🇸Chicago, Illinois, United States
Children's Hospital of Illinois
🇺🇸Peoria, Illinois, United States
Rainbow Babies at Children's Hospital
🇺🇸Cleveland, Ohio, United States
Oregon Health & Science University
🇺🇸Portland, Oregon, United States
Children's Hospital of Philadelphia
🇺🇸Philadelphia, Pennsylvania, United States
Kosair Children's Hospital, University of Louisville
🇺🇸Louisville, Kentucky, United States
Children's Hospital and Regional Medical Center
🇺🇸Seattle, Washington, United States